Antibody-based therapeutics targeting ILDR2, designated by Compugen as CGEN-15001T, for immuno-oncology were licensed to Bayer, while Compugen retains the full rights to the fusion protein ...

Do not miss out and become a member today for free to access this upcoming report at: Compugen, First to Publish Data on ILDR2 as a New Immune Checkpoint with a Therapeutic Role in Auto-Immune ...

BAY 1905254 is a novel immune checkpoint inhibitor for cancer immunotherapy targeting ILDR2. BAY 1905254 is a human/mouse cross-reactive antibody designed to block the immunosuppressive activity ...

BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting ILDR2 immune checkpoint discovered by Compugen, is currently being evaluated by Bayer in a Phase 1 study in advanced ...

BAY 1905254 is a first-in-class therapeutic antibody candidate targeting ILDR2, a novel immune checkpoint discovered by Compugen. Bayer plans to advance the program into first-in-human trials in 2018.

ILDR2 is a novel immune checkpoint discovered by Compugen through its predictive computational capabilities, which enable the discovery of new drug targets and biological pathways. Under a ...

The continued development of cancer drug BAY 1905254 is a major boost for Compugen's ability to successfully identify new mechanisms for treatments using its big data systems. ILDR2 is a new ...